The estimated Net Worth of Michael A Pisetsky is at least $3.41 Milion dollars as of 16 February 2023. Mr Pisetsky owns over 3,366 units of SI-BONE Inc stock worth over $2,544,629 and over the last 6 years he sold SIBN stock worth over $870,329.
Mr has made over 33 trades of the SI-BONE Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 3,366 units of SIBN stock worth $56,381 on 16 February 2023.
The largest trade he's ever made was exercising 10,136 units of SI-BONE Inc stock on 25 January 2022 worth over $43,788. On average, Mr trades about 1,616 units every 35 days since 2019. As of 16 February 2023 he still owns at least 168,742 units of SI-BONE Inc stock.
You can see the complete history of Mr Pisetsky stock trades at the bottom of the page.
Michael A. Pisetsky is the Sr. VP of Operations & Admin., Sec. and Chief Legal Officer at SI-BONE Inc.
Mr Pisetsky is 43, he's been the Sr. VP of Operations & Admin. i Sec. and Chief Legal Officer of SI-BONE Inc since . There are 28 older and 1 younger executives at SI-BONE Inc. The oldest executive at SI-BONE Inc is Valery Serdyukov, 74, who is the Non-Executive Director.
Michael's mailing address filed with the SEC is C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA, CA, 95050.
Over the last 6 years, insiders at SI-BONE Inc have traded over $114,943,926 worth of SI-BONE Inc stock and bought 1,250,000 units worth $18,750,000 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit... oraz John Gordon Freund. On average, SI-BONE Inc executives and independent directors trade stock every 8 days with the average trade being worth of $401,535. The most recent stock trade was executed by Anshul Maheshwari on 3 September 2024, trading 1,414 units of SIBN stock currently worth $23,119.
si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al
SI-BONE Inc executives and other stock owners filed with the SEC include: